Summary of Key Information:

Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Unaudited Standalone and Consolidated Financial Results

Audit Opinion:

Unmodified limited review report from statutory auditors Walker Chandiok & Co LLP

Key Financial Highlights [₹ in million]:

Standalone Results:

Revenue from Operations: ₹3,922.75 (Q1 FY27) vs ₹3,324.43 (Q1 FY26) - 18.0% YoY increase

Total Income: ₹4,183.79 (Q1 FY27) vs ₹3,609.98 (Q1 FY26) - 15.9% YoY increase

Net Profit: ₹448.39 (Q1 FY27) vs ₹448.67 (Q1 FY26) - relatively stable

EPS: ₹2.93 (Basic and diluted, face value ₹2 each)

Other Equity: Not specified for current quarter

Consolidated Results:

Revenue from Operations: ₹11,666.29 (Q1 FY27) vs ₹10,240.32 (Q1 FY26) - 13.9% YoY increase

Total Income: ₹11,970.09 (Q1 FY27) vs ₹10,507.63 (Q1 FY26) - 13.9% YoY increase

Net Profit: ₹1,009.78 (Q1 FY27) vs ₹646.85 (Q1 FY26) - 56.1% YoY increase

EPS: ₹6.53 (Basic and diluted, face value ₹2 each)

Other Equity: Not specified for current quarter

Segment-wise Performance:

The Group operates in five business segments:

Revenue from Operations (External Customers):

  • CDMO: ₹9,642.12 million (82.7% of total)
  • API: ₹316.46 million (2.7% of total)
  • Domestic Branded Formulations: ₹1,152.79 million (9.9% of total)
  • International Branded Formulations: ₹345.48 million (3.0% of total)
  • Trade Generics: ₹209.44 million (1.8% of total)

Segment Results:

  • CDMO: ₹1,265.28 million profit (93.4% of total segment profit)
  • API: ₹(81.46) million loss
  • Domestic Branded Formulations: ₹108.34 million profit (8.0% of total)
  • International Branded Formulations: ₹62.15 million profit (4.6% of total)
  • Trade Generics: ₹0.12 million profit (0.0% of total)

Corporate Actions:

Shareholders at Annual General Meeting held on July 10, 2026 approved final dividend of ₹1 per equity share and special dividend of ₹2 per equity share (aggregate ₹3 per equity share) for financial year ended March 31, 2026. Dividend paid subsequent to quarter end.

Other Significant Information:

  • Company operates in single segment 'Pharmaceuticals' at standalone level
  • ESOP Trust treated as extension of Company, shares netted off from paid-up share capital
  • Finance costs include ₹200.51 million from unwinding of significant financing component embedded in long-term customer advance
  • 15 subsidiaries included in consolidation